Abstracts tagged "tyk2"

Abstract Number: 0490 • ACR Convergence 2021
Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in PsA: Effects on Disease Markers and Tyrosine Kinase 2‒ versus Janus Kinase 1/2/3‒mediated Pathways
Oliver FitzGerald¹, Dafna Gladman², Philip Mease³, Christopher Ritchlin⁴, Josef Smolen⁵, Lu Gao⁶, Sarah Hu⁶, Miroslawa Nowak⁶, Subhashis Banerjee⁶, Ian Catlett⁶ and Xiang Guo⁶, ¹Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁵Medical University of Vienna, Vienna, Austria, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib is a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action that has demonstrated efficacy in patients (pts)…
Abstract Number: 1352 • ACR Convergence 2021
Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Exploratory Analysis from a Phase 2 Study
Atul Deodhar¹, Miroslawa Nowak², June Ye², Tom Lehman², Lan Wei², Subhashis Banerjee² and Philip Mease³, ¹Oregon Health & Science University, Portland, OR, ²Bristol Myers Squibb, Princeton, NJ, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: PsA presents with heterogeneous clinical manifestations including joint pain, enthesitis, dactylitis, and skin and nail lesions. Treatment guidelines recommend that PsA patients (pts) who…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].